A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

This is an interventional treatment trial for Advanced Gastric Carcinoma Read More

Inclusion Criteria:

1. Subjects fully understand and voluntarily participate in this study and sign informed consent;
2. Age ≥18, without gender limitation;
3. Histologically confirmed diagnosis of unresectable locally advanced or metastatic gastric carcinoma, including gastroesophageal junction carcinoma;
4. Suitable to receive the study drug as decided by the investigator;
5. At least one measurable lesion according to RECIST v1.1;
6. ECOG performance status of 0 to 2;
7. Life expectancy ≥ 12 weeks;
8. AEs from the previous treatment have resolved to ≤ Grade 1 based on CTCAE (except for the toxicity without safety risk judged by the investigator, such as hair loss, hyperpigmentation);
9. Adequate organ function;
10. Subjects of childbearing potential must agree to use effective contraceptive measures. Female subjects must have a negative pregnancy test before enrolment;
11. Fully comply with the protocol.

Exclusion Criteria:

1. History of allergy to mitoxantrone hydrochloride or any excipients of the study drug;
2. Untreated or symptomatic central nervous system (CNS) metastases;
3. Amenable to curative surgery ( radical excision);
4. Pleural effusion, pericardial effusion or peritoneal effusion with overt clinical symptoms (except for those have a drainage within 1 month before screening, asymptomatic and the effusion only detectable by imageological examination);
5. Intestinal obstruction with overt clinical symptom and requiring treatment;
6. CTCAE Grade 3 or Grade 4 gastrointestinal hemorrhage within 12 weeks prior to the first dose administration;
7. History of allotransplantation;
8. Known hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or other active viral infection;
9. Serious infection or interstitial pneumonia within 1 week prior to the first dose administration;
10. Use of other anticancer treatment within 4 weeks prior to the first dose administration;
11. Enrolled in any other clinical trails and had recieved treatment within 4 weeks prior to the first dose administration;
12. Major surgery within 3 months prior to the first dose administration, or have a surgical schedule during the study period;
13. Thrombosis or thromboembolism within 6 months prior to screening;
14. History of, or known additional malignant tumor within 3 years, except for tumors have been cured and have not recurred, and carcinoma in situ;
15. Impaired cardiac function or serious cardiac disease;
16. Previous treatment with adriamycin or other anthracyclines, and the total cumulative dose of prior adriamycin or equivalent is >350 mg/m2.
17. Pregnant or lactating female;
18. Serious and/or uncontrolled systemic diseases;